Skip to content

A clinical application study of metabolomics/miRNA in the treatment of IV stage Diabetic kidney disease patients with nourishing Yang and removing stasis method

A clinical application study of metabolomics/miRNA in the treatment of IV stage Diabetic kidney disease patients with nourishing Yang and removing stasis method

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000158
Enrollment
Unknown
Registered
2024-08-01
Start date
2023-01-01
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic kidney disease

Interventions

Moxibustion medicine combination group:Basic treatment+Yiyang Sanjie Formula+Yiyang dispersing moxibustion therapy
Control group:Basic treatment
Yiyang Sanjie Formula group:Basic treatment+Yiyang Sanjie Formula

Sponsors

Yirui Zhao
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) A definite history of diabetes; (2) Ages between 40 and 75 years old, gender not specified; (3) Blood pressure controlled within the range of 90-130mmHg/70-90mmHg; (4) Meet the diagnostic criteria for type 2 diabetes in phase IV of the Chinese Medical Association Diabetes Branch's Guidelines for the Prevention and Treatment of Diabetes in China (2020); (5) Inclusion of patients who meet the criteria for yang deficiency and blood stasis according to traditional Chinese medicine; (6) Understand the entire process of the trial and voluntarily participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients in stages I, II, III, and V of DKD; (2) Patients diagnosed with type 1 diabetes or other types of diabetes; (3) Primary renal diseases and other secondary renal diseases not caused by diabetes; (4) Patients with diabetic ketoacidosis and urinary tract infections within the past month; (5) Patients with other serious organic diseases (such as cardiovascular diseases, severe hematological diseases, tumors, etc.); (6) Women during pregnancy or lactation; (7) Patients with mental illness or non-compliance with instructions; (8) Patients with a history of allergies or sensitivity to other drugs; (9) Other patients participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
UAER;24hpro;Serum creatinine;Metabolomics testing;Urinary exosomal miRNAs;Urea nitrogen;

Secondary

MeasureTime frame
eGFR;HbA1c;FBG;Urinary nag enzyme;

Countries

China

Contacts

Public ContactYirui Zhao

Shanxi Integrated Traditional Chinese and Western Medicine Hospital

zyr1007@126.com+8613835111546

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026